The GH-releasing effect of acylated ghrelin in normal subjects is refractory to GH acute auto-feedback but is inhibited after short-term GH administration inducing IGF1 increase by Benso, A. et al.
This full text was downloaded from iris - AperTO: https://iris.unito.it/
iris - AperTO
University of Turin’s Institutional Research Information System and Open Access Institutional Repository
This is the author's final version of the contribution published as:
A. Benso;E. Gramaglia;I. Olivetti;M. Tomelini;V. R. Gigliardi;S. Frara;E.
Calvi;S. Belcastro;D. H. St Pierre;E. Ghigo;F. Broglio. The GH-releasing
effect of acylated ghrelin in normal subjects is refractory to GH acute
auto-feedback but is inhibited after short-term GH administration inducing
IGF1 increase. EUROPEAN JOURNAL OF ENDOCRINOLOGY. 168 pp:
509-514.
DOI: 10.1530/EJE-12-0691
The publisher's version is available at:
http://www.eje-online.org/cgi/doi/10.1530/EJE-12-0691
When citing, please refer to the published version.
Link to this full text:
http://hdl.handle.net/2318/131207
1 
 
The GH-releasing effect of acylated ghrelin in normal subjects is refractory to GH acute auto-
feedback but is inhibited after short-term GH administration inducing IGF1 increase 
 
 A Benso*, E Gramaglia*, I Olivetti, M Tomelini, V Ramella Gigliardi, S Frara, E Calvi, S Belcastro, D 
H St Pierre, E Ghigo and F Broglio  
 
 Division of Endocrinology, Diabetology and Metabolism, Department of Internal Medicine, San 
Giovanni Battista, Molinette Hospital, University of Turin, Corso Dogliotti 14, 10126 Turin, Italy 
 
 (Correspondence should be addressed to F Broglio; Email: fabio.broglio@unito.it) 
 
* (A Benso and E Gramaglia contributed equally to this work) 
  
2 
 
Abstract 
Objective: GH secretion is regulated by an interplay between GH-releasing hormone (GHRH), 
somatostatin (SST), and other central and peripheral signals. Acylated ghrelin (AG) amplifies GH 
pulsatility acting, at least partially, independently from GHRH and SST. The GH response to GHRH 
is inhibited by recombinant human GH (rhGH), likely due to a SST-mediated negative GH auto-
feedback. The effect of exogenous rhGH on the GH-releasing effect of AG has never been tested. 
Design and methods: In six healthy volunteers, we studied the GH response to acute AG 
administration (1.0 μg/kg i.v.) during saline or rhGH infusion (4.0 μg/kg per h i.v.) or after 4-day 
rhGH (10.0 μg/kg s.c.) administration. 
Results: Compared with saline, rhGH infusion increased GH levels (P<0.01). During saline, acute i.v. 
AG induced a marked increase (P<0.01) in GH levels similar to those observed after AG 
administration during rhGH infusion. During s.c. rhGH, IGF1 levels rose from day 0 to day 5 
(P<0.01). After 4-day s.c. rhGH, i.v. AG increased (P<0.01) GH levels, though significantly (P<0.05) 
less than on day 0. 
Conclusions: The marked somatotroph-releasing effect of AG is refractory to a direct GH auto-
feedback whereas is markedly inhibited after 4-day rhGH administration, suggesting the possibility 
of a selective IGF1-mediated inhibitory feedback. 
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Introduction 
The neural control of GH secretion mainly depends on the tight interplay between GH-releasing 
hormone (GHRH) and somatostatin (SST) (1, 2, 3, 4, 5, 6). In addition, several neurotransmitters, 
neuropeptides, metabolic fuels, and also peripheral hormones, in particular insulin-like growth 
factor 1 (IGF1), have an important influence on somatotropic function mainly acting via the 
modulation of GHRH and SST release (7, 8). In particular, the negative feedback exerted by IGF1 on 
GH secretion involves direct effects at the pituitary level through activation of IGF1 receptors, 
leading to the inhibition of GH synthesis and release (9). Indirect CNS-mediated mechanisms have 
also been demonstrated. In fact, in animals, IGF1 has been shown to be able to stimulate SST and 
inhibit GHRH release acting at the hypothalamic level (9). GH itself, directly and indirectly, 
modulates its own secretion, and this negative GH auto-feedback control involves many of the 
above-mentioned factors (1, 2, 3, 4, 5, 6, 7, 8). GH increases IGF1 and free fatty acid levels, which 
in turn inhibits GH secretion acting both at the pituitary and hypothalamic level (10, 11). However, 
the influence of IGF1 and free fatty acids does not account for the inhibitory effect shown by the 
acute administration of GH on the GH response to GHRH both in animals and in man that is 
instead mediated by SST (12). SST antiserum in rat and substances inhibiting hypothalamic SST 
release in man are able to completely restore the GH response to GHRH when inhibited by a 
previous recombinant human GH (rhGH) bolus (12, 13, 14, 15, 16, 17). In recent years, the 
complexity of the regulation of the GH/IGF1 axis has been further enriched by the discovery of 
ghrelin, a peptidic hormone mainly deriving from gastric production that, in its acylated form, 
displays a potent GH-releasing activity via the activation of a specific receptor, the GH 
secretagogues (GHS) receptor type 1a (GHSR1a) (18, 19, 20, 21). Although many years have passed 
since its isolation, the actual role of acylated ghrelin (AG) in the physiological control of GH 
secretion is still a matter of debate and is likely to act as an amplifier of GH pulsatility rather than a 
true GH pulse generator as an alternative GHRH (22, 23). Although the physiological role of AG in 
the control of the somatotropic axis is probably less relevant than originally expected, anyway it 
remains that the exogenous administration of AG as well as its synthetic analogues such as 
hexarelin or GHRP6 represents one of the most potent pharmacological stimuli of GH secretion in 
humans in vivo (20, 24, 25). Notably, despite this evidence, no information is available in the 
literature on the influence of GH and IGF1 levels themselves on the somatotroph responsiveness 
to AG in physiological conditions. Based on the foregoing, the aim of this study was to verify 
whether the GH-releasing effect of AG is influenced by the acute increase in GH levels induced by 
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short-term infusion of rhGH and/or by the increase in IGF1 levels induced by 4-day s.c. rhGH 
administration in adult healthy volunteers. In order to test the specificity of GH or IGF1 feedback 
on the GH-releasing effect of AG, the effects on the prolactin (PRL) and cortisol responses to the 
gastric hormone were also evaluated. 
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Materials and methods 
Six healthy young male volunteers (age (mean±s.e.m.), 27.8±3.1 years; BMI, 23.1±2.3 kg/m2) were 
studied. All the subjects gave their written informed consent to participate in the study, which had 
been approved by the Ethics Committee of the University of Turin. All the subjects underwent the 
following three testing sessions in random order at least 30 days apart: i) acute AG administration 
(1.0 μg/kg i.v. as a bolus at 0′) during saline infusion from −180′ to +60′; ii) acute AG administration 
(1.0 μg/kg i.v. as a bolus at 0′) during rhGH (4.0 μg/kg per h) i.v. infusion from −180′ to +60′; and iii) 
acute AG administration (1.0 μg/kg i.v. as a bolus at 0′) during saline infusion from −180′ to +60′ 
after 4-day rhGH (10.0 μg/kg) s.c. administration at 2100 h. 
After overnight fasting, the tests began in the morning at 0830–0900 h, 30′ after an indwelling 
catheter had been placed into an antecubital vein of the forearm kept patent by slow infusion of 
isotonic saline. 
Blood samples were taken every 15 min from time −180′ up to +60′. GH, PRL, and cortisol levels 
were assayed at each time point in all the sessions. IGF1 levels were assayed at −180′ and at +60′ 
in each session. IGF1, IGFBP3, GH, free fatty acids, insulin, and glucose were assayed at time 0′ in 
each session and at 0800 h on the following day after every evening rhGH s.c. administration. 
GH levels (μg/l) were measured in duplicate by immunoradiometric assay (IRMA; hGH–CT, RADIM, 
Pomezia, Italy): sensitivity, 0.04 μg/l; inter- and intra-assay coefficient of variation (CV) range, 4.6 
and 3.7% respectively. IGF1 levels (ng/ml) were measured in duplicate by IRMA (IGF1 SM-C-RIA-
CT, PANTEC, Torino, Italy): sensitivity, 0.25 ng/ml; inter- and intra-assay CV range, 10.8 and 9.5% 
respectively. IGFBP3 levels (μg/ml) were measured in duplicate by IRMA (IGFBP3 IRMA, 
IMMUNOTECH SA, Marseille, France): sensitivity, 0.050 μg/ml; inter- and intra-assay CV range, 9.5 
and 6.0% respectively. 
Cortisol levels (μg/dl) were measured in duplicate by IRMA (RADIM): sensitivity, 0.09 μg/dl; inter- 
and intra-assay CV range, 7.2 and 8.0% respectively. PRL levels (ng/ml) were measured in duplicate 
by IRMA (PANTEC): sensitivity, 0.5 ng/ml; inter- and intra-assay CV range, 8.0 and 2.8% 
respectively. Plasma glucose levels (mg/dl; 1 mg/dl=0.05551 mmol/l) were measured by the 
glucose oxidase colorimetric method (GLUCOFIX; Menarini Diagnostics, Florence, Italy). 
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Serum insulin levels (μU/ml) were measured in duplicate by IRMA (INSIK-5; SORIN Biomedica, 
Saluggia, Italy). The sensitivity of the insulin assay was 2.5±0.3 μU/ml. The inter- and intra-assay CV 
values were 6.2–10.8 and 5.5–10.6% respectively. 
Serum free fatty acid (FFA) levels (mEq/l) were measured by enzymatic colorimetric method 
(Wako Chemicals GmbH, Neuss, Germany). The inter- and intra-assay CV values were 1.1 and 4.1% 
respectively. All the samples from an individual subject were analyzed in a single run of each assay. 
All samples from an individual subject were analyzed together. 
The hormonal responses are expressed as absolute mean levels or areas under the curves (AUCs) 
calculated by trapezoidal integration. The statistical analysis was carried out using nonparametric 
ANOVA (Mann–Whitney U test), as appropriate. The results are expressed as mean±s.e.m. 
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Results 
Mean (±s.e.m.) GH levels during saline infusion were 0.6±0.1 μg/l corresponding to an 
AUCsalinet−180′–t0′ of 111.0±56.0 μg/l×min. During rhGH infusion starting at −180′, GH levels 
progressively rose up to a steady-state level at time −135′; in particular, mean GH levelst−135′–t0′ 
were 29.8±2.6 μg/l corresponding to an AUCrhGHt−135′–t0′ of 3336.0±171.0 μg/l×min, which as 
expected, was significantly higher (P<0.01) than that observed during saline at the corresponding 
time points (AUCsalinet−135′–t0′: 93.0±60.0 μg/l×min; Fig. 1).  
Mean ±SEM GH responses to acute AG administration (1.0 μg/kg i.v.) during saline or rhGH 
infusion (4.0 μg/kg/h i.v.) or after 4-day rhGH (10.0 μg/kg s.c.) administration. AG, acylated 
ghrelin; rhGH, recombinant human GH. During saline infusion, the acute i.v. AG administration 
induced a marked increase (P<0.01) in GH levels (Δpeaksaline+AGt0′–t60′, 53.0±5.8 μg/l; 
ΔAUCsaline+AGt0′–t60′, 2054.0±161.0 μg/l×min) that were not different from that observed after 
acute i.v. AG administration during rhGH infusion (ΔpeakrhGH+AGt0′–t60′, 55.6±10.0 μg/l; 
ΔAUCrhGH+AGt0′–t60′, 1962.0±319.0; Fig. 2). IGF1, IGFBP3, glucose, and insulin levels both at 
time 0′ and at time 60′ were similar in both sessions (data not shown).  
Mean ±SEM ΔAUC 0′-60′ GH responses to acute AG administration (1.0 μg/kg i.v.) during saline or 
rhGH infusion (4.0 μg/kg/h i.v.) or after 4-day rhGH (10.0 μg/kg s.c.) administration. ΔAUC, Δ area 
under the curve; AG, acylated ghrelin; rhGH, recombinant human GH. During treatment with 
10.0 μg/kg per day rhGH, IGF1 levels progressively rose from day 0 levels (212.2±15.6 μg/l) 
reaching statistical significance on day 3 (287.5±26.6 μg/l; P<0.01 vs baseline) and then showed a 
further increase on day 4 (306.2±36.9 μg/l; P<0.01 vs baseline) (Fig. 3). As expected, a concomitant 
increase (P<0.05) in GH levels was also observed (day 0, 0.2±0.1 μg/l; day 3, 1.2±0.7 μg/l; day 4, 
1.4±0.9 μg/l; Fig. 3). On the contrary, no significant variations in IGFBP3, insulin, free fatty acids, 
and glucose levels were observed after 4-day rhGH s.c. treatment (data not shown).  
Mean ±SEM GH and IGFI levels at baseline (D0) and during 4-day rhGH (10.0 μg/kg s.c.) treatment 
(from D1 to D4). D0, day 0; D1, day 1; D2, day 2; D3, day 3; D4, day 4. After 4-day s.c. rhGH 
treatment, the i.v. administration of AG induced a significant increase (P<0.01) in GH levels 
(Δpeakpost-rhGH+AGt0′–t60′, 19.0±4.1 μg/l; ΔAUCpost-rhGH+AGt0′–t60′, 753.0±174.0 μg/l×min) 
that was, however, significantly (P<0.05) lower than that observed on day 0 (Fig. 2). As expected, 
the administration of AG on day 0 also induced significant increases in PRL and cortisol levels 
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(P<0.05) that were similar to those observed after AG during rhGH i.v. administration or after 4-
day rhGH s.c. administration (Table 1). In all the sessions, baseline PRL and cortisol levels were 
similar (data not shown). Ghrelin administration induced a transient facial flushing in two subjects. 
No side effects during rhGH i.v. or s.c. administration were observed. Mean (±s.e.m.) PRL and 
cortisol responses to acute AG administration (1.0 μg/kg i.v.) during saline or rhGH infusion 
(4.0 μg/kg per h i.v.) or after 4-day rhGH (10.0 μg/kg s.c.) administration. 
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Discussion 
The results of this study show that the somatotroph-releasing effect of AG is refractory to the 
direct inhibitory effect of a short-term elevation of GH levels without increase in IGF1 levels, while 
it is markedly inhibited in the presence of increased IGF1 levels induced by 4-day rhGH 
administration. AG has been isolated as an endogenous ligand of the GHSR1a and emerged as one 
of the most potent and reproducible gender-independent stimuli of GH secretion in vivo during 
the lifespan (18, 19, 20, 21). The GH-releasing effect of AG is mediated by actions on the pituitary 
and, mainly, within the hypothalamus, in particular, through a positive action on GHRH-secreting 
neurons and a concomitant functional antagonism of SST activity (26). Different from GHRH, the 
GH-releasing activity of AG has already been reported to be refractory to the most important 
inhibitory inputs on GH secretion such as glucose, free fatty acids and β-adrenergic stimulation, all 
acting to increase the hypothalamic SST release (26), and even to be resistant to the inhibitory 
effect of SST administration itself (26, 27). Thus, our present observation that a short-term 
increase in circulating GH levels induced by rhGH i.v. infusion fails to inhibit the GH response to AG 
is not surprising. In fact, it is well accepted both in animals and in humans that the negative GH 
auto-feedback mechanism is mainly mediated by the release of hypothalamic SST (28, 29). On the 
other hand, interestingly, our data clearly show that the GH response to AG is markedly inhibited 
after 4-day s.c. rhGH administration, able to induce a significant increase in IGF1 levels, though still 
in the normal range, without sensible variations in circulating GH levels. Although a definitive 
proof cannot be drawn by our experimental model, the negative correlation we observed between 
the changes in the GH responses to AG and in IGF1 levels before and after s.c. rhGH treatment 
(data not shown) might suggest a causative relationship between the two phenomena, i.e. the 
possibility of a selective inhibitory effect of IGF1 on the GH-releasing effect of AG. Notably, a 
definitive demonstration of this hypothesis could derive from the evaluation of the effects of the 
direct administration of exogenous IGF1 on the GH response to AG, provided that IGF1 is 
administered at a dose not able to modify spontaneous GH secretion. Actually, in our study, the 
dose of 10 μg/kg rhGH was chosen as the one previously reported to be the minimal effective to 
increase IGF1 levels in both males and females (30). There is a wealth of in vitro and in vivo animal 
data showing that IGF1 inhibits GH release acting either at the pituitary or the hypothalamic level 
(31, 32) via inhibition of GHRH and/or stimulation of SST release (29, 31). As the GH-releasing 
activity of AG is supposed to be mediated by functional antagonism of SST activity at both the 
pituitary and the hypothalamic level, it is unlikely that the inhibitory effect of rhIGF1 on the GH 
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response to AG takes place via activation of somatostatinergic pathways (33). Thus, as there is 
evidence that IGF1 inhibits hypothalamic GHRH release, it is likely that the inhibitory effect of IGF1 
on the GH response to AG might be mediated by counteracting its stimulatory effect on GHRH 
neuron activity (33). Alternatively, the possibility of a direct effect at the pituitary level cannot be 
excluded. In fact, prolonged exposure to GH has been reported to be able to decrease GHSR1a 
mRNA levels both at the pituitary and the hypothalamic level in rats (34, 35, 36) through IGF1-
independent mechanisms (36). Unfortunately, our study model in vivo in humans does not allow 
to distinguish the pituitary from the hypothalamic effects, nor to fully define the distinct role of 
the 4-day GH exposure or of the increased IGF1 levels per se. However, the hypothesis of a 
mechanism involving the modulation of GHSR1a level seems unlikely as both the responses of PRL 
and cortisol (due to the ACTH-releasing effect) to AG are not modified by either acute or 
prolonged rhGH administration. In fact, though elicited at different sites (e.g. lactotroph cells in 
the pituitary and CRH/AVP-secreting cells in the hypothalamus respectively), both actions have 
been clearly shown to be mediated by the activation of GHSR1a itself (21, 37). Similarly, the 
hypothesis that the impairment of the GH response to AG after 4-day rhGH treatment could be 
mediated by other factors than the increase in IGF1 levels has to be considered. In fact, prolonged 
GH treatment has been reported to increase glucose and free fatty acids levels (38). However, as 
reported before, the GH response to AG has been clearly shown to be refractory to the inhibitory 
effect of both glucose and free fatty acids (26), and moreover, in this study, no significant variation 
of glucose and free fatty acids levels were detected after rhGH treatment. On the contrary, 
although circulating AG and unacylated ghrelin levels were not assayed, the theoretical possibility 
that the different GH responses could be related to inter-session differences in blood AG levels 
after i.v. administration is very unlikely as the test order was randomized and each subject 
received the same i.v. AG dose in each session. Similarly, the hypothesis that the impaired GH 
response to AG after 4-day s.c. GH administration is related to a random effect is very remote 
despite the lack of a control arm, taking into account the well known high intra-subject 
reproducibility of the somatotroph responsiveness to natural and synthetic GHS (20) and F Broglio, 
unpublished results). In conclusion, our results indicate that the somatotroph-releasing effect of 
AG is refractory to the direct inhibitory effect of a short-term elevation of GH levels while it is 
markedly inhibited in the presence of increased IGF1 levels induced by 4-day rhGH administration, 
opening the possibility, in agreement with previous studies with synthetic GHS (33), of a selective 
IGF1-mediated feedback. 
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Figures 
 
Figure 1 Mean ±SEM GH responses to acute AG administration (1.0 μg/kg i.v.) during saline or 
rhGH infusion (4.0 μg/kg/h i.v.) or after 4-day rhGH (10.0 μg/kg s.c.) administration. AG, acylated 
ghrelin; rhGH, recombinant human GH. 
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Figure 2 Mean ±SEM ΔAUC 0′-60′ GH responses to acute AG administration (1.0 μg/kg i.v.) during 
saline or rhGH infusion (4.0 μg/kg/h i.v.) or after 4-day rhGH (10.0 μg/kg s.c.) administration. 
ΔAUC, Δ area under the curve; AG, acylated ghrelin; rhGH, recombinant human GH. 
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Figure 3 Mean ±SEM GH and IGFI levels at baseline (D0) and during 4-day rhGH (10.0 μg/kg s.c.) 
treatment (from D1 to D4). D0, day 0; D1, day 1; D2, day 2; D3, day 3; D4, day 4. 
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Table 1 Mean (±s.e.m.) PRL and cortisol responses to acute AG administration (1.0 μg/kg i.v.) 
during saline or rhGH infusion (4.0 μg/kg per h i.v.) or after 4-day rhGH (10.0 μg/kg s.c.) 
administration.  
 
PRL ΔAUCt0′–t60′ 
(ng/ml×min)  
Cortisol ΔAUCt0′–t60′ 
(μg/dl×min)  
P vs 
saline+AG 
Saline+AG 398.3±95.1 4079.0±835.2 – 
rhGH i.v.+AG 210.8±45.4 2644.8±764.9 NS 
Saline+AG after 4-day rhGH 
s.c. 
399.8±164.0 3469.1±818.2 NS 
 PRL, prolactin; ΔAUC, Δ area under the curve; AG, acylated ghrelin; rhGH, recombinant 
human GH; NS, not significant. 
 
